SOA Wealth Advisors’s BridgeBio Pharma BBIO Stock Holding History

SOA Wealth Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-98	Closed	-$7.3K	–	853
2026 Q2	$7.3K	Buy	+98	New	+$6.86K	﹤0.01%	655

Other funds holding BBIO

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

SOA Wealth Advisors's BBIO Position: Q3 2026 in Review

SOA Wealth Advisors sold out of BridgeBio Pharma (BBIO) in Q3 2026, closing a stake of 98 shares — an estimated $7.3K sold.

SOA Wealth Advisors first reported a position in BBIO in Q2 2026 and held it in 1 quarter. The position peaked at $7.3K in Q2 2026. 290 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

SOA Wealth Advisors reported no remaining BridgeBio Pharma position as of Q3 2026 after selling out during the quarter.
SOA Wealth Advisors sold 98 BridgeBio Pharma shares in Q3 2026, an estimated $7.3K.
SOA Wealth Advisors first reported a position in BridgeBio Pharma in Q2 2026 and held it in 1 quarter.
SOA Wealth Advisors's BridgeBio Pharma position peaked at $7.3K in Q2 2026.
290 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on SOA Wealth Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.